Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
| العنوان: | Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses |
|---|---|
| المؤلفون: | Xiaohui Pan, Bo Yang, Hongjie Guo, Shuyuan Cheng, Xi Chen, Ling Ding, Qiaojun He, Wenxin Zhang |
| المصدر: | Acta Pharmaceutica Sinica B, Vol 10, Iss 5, Pp 723-733 (2020) Acta Pharmaceutica Sinica. B |
| بيانات النشر: | Elsevier BV, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | TIM-3, T cell immunoglobulin and mucin domain 3, H3K27me3, tri-methylation of lysine 27 on histone H3, MDSCs, myeloid-derived suppressor cells, medicine.medical_treatment, Review, TAA, tumor-associated antigen, DC, dendritic cell, 0302 clinical medicine, EZH2, enhancer of zeste homolog 2, LAG-3, lymphocyte activation gene-3, CTLA-4, cytotoxic T lymphocyte antigen 4, Medicine, BETi, bromodomain and extra-terminal motif inhibitors, General Pharmacology, Toxicology and Pharmaceutics, FOXP3, forkhead box P3, HDACi, histone deacetylase inhibitor, Cancer, 0303 health sciences, ACE1, angiotensin converting enzyme, CLL, chronic lymphocytic leukemia, biology, IDO, indoleamine 2,3-dioxygenase, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Tregs, regulatory T cells, PD-L1/PD-1 blockade, CCL22 (MDC), macrophage-derived chemokine, Immunotherapy, TET2, ten-eleven translocation 2, CTLs, cytotoxic T lymphocytes, FDA, U. S. Food and Drug Administration, PD-L1, programmed cell death ligand 1, T cell, CTA, cancer testis antigen, Immune cycle, TIL, tumor infiltrating lymphocytes, Epigenetic regulation, OS, overall survival, 03 medical and health sciences, Immune system, Antigen, PD-L1, TH-1, T helper type 1, DNMT1, DNA methyltransferase 1, MHC, major histocompatibility complex, CX3CL1, C-X3-C motif chemokine ligand 1, IFN-γ, interferon-gamma, 030304 developmental biology, business.industry, lcsh:RM1-950, biochemical phenomena, metabolism, and nutrition, medicine.disease, CXCL, CXC chemokine ligand, Blockade, lcsh:Therapeutics. Pharmacology, APC, antigen-presenting cell, UHRF1, ubiquitin-like PHD and RING finger domain-containing 1, 5-AzaC, 5-azacitidine, ACP1, human red cell acid phosphatase, biology.protein, Cancer research, bacteria, DNMTi, DNA methyltransferase inhibitors, PD-1, programmed cell death 1, business, PRC2, polycomb repressive complex 2 |
| الوصف: | Immunotherapy strategies targeting the programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) pathway in clinical treatments have achieved remarkable success in treating multiple types of cancer. However, owing to the heterogeneity of tumors and individual immune systems, PD-L1/PD-1 blockade still shows slow response rates in controlling malignancies in many patients. Accumulating evidence has shown that an effective response to anti-PD-L1/anti-PD-1 therapy requires establishing an integrated immune cycle. Damage in any step of the immune cycle is one of the most important causes of immunotherapy failure. Impairments in the immune cycle can be restored by epigenetic modification, including reprogramming the environment of tumor-associated immunity, eliciting an immune response by increasing the presentation of tumor antigens, and by regulating T cell trafficking and reactivation. Thus, a rational combination of PD-L1/PD-1 blockade and epigenetic agents may offer great potential to retrain the immune system and to improve clinical outcomes of checkpoint blockade therapy. Graphical abstract An effective response to anti-PD-L1/anti-PD-1 therapy requires the establishment of an integrated immune cycle. Impaired immune cycle can be restored by epigenetic modification, including reprogramming the tumor-associated immunity and eliciting an immune response. Epigenetic combination therapies may be optimally integrated to enhance the response rates of PD-L1/PD-1 blockade.Image 1 |
| تدمد: | 2211-3835 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1ca7b0479f6fea7a89a3e1eb06905c5Test https://doi.org/10.1016/j.apsb.2019.09.006Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....d1ca7b0479f6fea7a89a3e1eb06905c5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 22113835 |
|---|